147 related articles for article (PubMed ID: 34638492)
1. Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures.
Vasudevan S; Adejumobi IA; Alkhatib H; Roy Chowdhury S; Stefansky S; Rubinstein AM; Kravchenko-Balasha N
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638492
[TBL] [Abstract][Full Text] [Related]
2. Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer.
Alkhatib H; Conage-Pough J; Roy Chowdhury S; Shian D; Zaid D; Rubinstein AM; Sonnenblick A; Peretz-Yablonsky T; Granit A; Carmon E; Kohale IN; Boughey JC; Goetz MP; Wang L; White FM; Kravchenko-Balasha N
Mol Cancer; 2024 Jan; 23(1):17. PubMed ID: 38229082
[TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes.
Jubran MR; Vilenski D; Flashner-Abramson E; Shnaider E; Vasudevan S; Rubinstein AM; Meirovitz A; Sharon S; Polak D; Kravchenko-Balasha N
Theranostics; 2022; 12(3):1204-1219. PubMed ID: 35154483
[TBL] [Abstract][Full Text] [Related]
4. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai K; Hung MC; Yamaguchi H
Am J Cancer Res; 2016; 6(8):1609-23. PubMed ID: 27648353
[TBL] [Abstract][Full Text] [Related]
5. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
Itoh T; Hatano R; Horimoto Y; Yamada T; Song D; Otsuka H; Shirakawa Y; Mastuoka S; Iwao N; Aune TM; Dang NH; Kaneko Y; Okumura K; Morimoto C; Ohnuma K
Cell Death Dis; 2021 May; 12(6):520. PubMed ID: 34021125
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
8. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
9. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
11. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
[TBL] [Abstract][Full Text] [Related]
12. Near-infrared photothermal therapy using EGFR-targeted gold nanoparticles increases autophagic cell death in breast cancer.
Zhang M; Kim HS; Jin T; Moon WK
J Photochem Photobiol B; 2017 May; 170():58-64. PubMed ID: 28390259
[TBL] [Abstract][Full Text] [Related]
13. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
[TBL] [Abstract][Full Text] [Related]
14. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.
Si Y; Xu Y; Guan J; Chen K; Kim S; Yang ES; Zhou L; Liu XM
Eng Life Sci; 2021 Jan; 21(1-2):37-44. PubMed ID: 33531889
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
17. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
20. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
